Clinical trials in Hochheim Am Main – page 42

1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Hochheim Am Main at a glance

1 444

clinical trials

Research sites1

Quick filters

1 444 trials in Hochheim Am Main

Open in trial search

Dementia+5

Recruiting

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Flutemetamol (18F)
Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Contact Research Centre

Mucopolysaccharidosis II

Recruiting

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years
Sponsor:Denali Therapeutics Inc.

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Contact Research Centre

Hormone receptor positive breast cancer+1

Recruiting

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:KITE-363
Sponsor:Kite Pharma Inc.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Mantle cell lymphoma stage II+2

Recruiting

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Klinikum der Universitaet Muenchen AöR

Contact Research Centre

Type IIa hyperlipidaemia

Recruiting

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Inclisiran
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Caffeine
Sponsor:UCB Biopharma

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Caffeine
Sponsor:UCB Biopharma

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Psoriasis

Recruiting

Study on Risankizumab for Children Aged 6-17 With Moderate to Severe Plaque Psoriasis After Completing Previous Study

InvestigationalNo placebo

Study on Risankizumab for Children Aged 6-17 With Moderate to Severe Plaque Psoriasis After Completing Previous Study

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:Risankizumab
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Hochheim Am Main

What the registry says about research in the country

01 Rare Genetic Disorders

Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.

Gaucher Disease TYPE 3 Treatment
Niemann-Pick Disease Management
Genetic Disease Therapies

Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.

02 Lysosomal Storage Disorders

Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.

Hunter Syndrome Treatment
Infantile-onset Pompe Disease
Late-onset Pompe Disease

Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.

03 Respiratory Diseases

Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.

RSV Prevention
Vaccine Development
Immune Response Studies

Investigation of revaccination strategies and long-term protection against respiratory infections.

Back to Germany All countries